Top 30 Pharmaceutical Company Signs Agreement with eResearchTechnology for Cardiac Safety Monitoring and Information Distributio
November 13 2003 - 8:06AM
PR Newswire (US)
Top 30 Pharmaceutical Company Signs Agreement with
eResearchTechnology for Cardiac Safety Monitoring and Information
Distribution Services Award Totals Approximately $1.2 Million for
Thorough Phase I ECG Study to be Completed by the End of the First
Quarter of 2004 PHILADELPHIA, Nov. 13 /PRNewswire-FirstCall/ --
eResearchTechnology, Inc. (eRT), , a leading provider of
centralized electrocardiographic (ECG) collection and
interpretation services, announced today that it has received an
agreement for approximately $1.2 million in cardiac safety
monitoring and services from a top 30 pharmaceutical organization
for one of its drug candidates in clinical trials. The agreement
covers an extensive Phase I study for which eRT is providing
comprehensive support including the provision, training and ongoing
assistance required for effective use of digital 12-lead Holter
equipment designed to facilitate 24-hour digital recording of
cardiac safety data that is subsequently provided to eRT for
analysis. eRT will perform digital collection, measurement,
interpretation, review, and distribution of cardiac safety data
through its EXPeRT workflow enabled data handling technology, the
first solution in production that was designed explicitly to meet
emerging international regulatory guidance and technical standards.
The study is targeted for completion by the end of the first
quarter of 2004. "This agreement marks the award of another
Thorough Phase I ECG Study for eRT and strengthens our position as
the leading provider of cardiac safety services in this important
new segment," said Scott Grisanti, senior vice president of
business development and chief marketing officer at eRT.
"Increasingly, new drug developers are recognizing eRT's unique
blend of science, process and technology that has been applied to
meet the demands of this new type of ECG study, which includes a
significant number of ECGs that must be recorded and analyzed in a
short timeframe." Based in Philadelphia, PA, eResearchTechnology,
Inc. (http://www.ert.com/) is a provider of technology and services
to the pharmaceutical, biotechnology and medical device industries
on a global basis. The company is a market leader in providing
centralized core-diagnostic electrocardiographic (ECG) technology
and services to evaluate cardiac safety in clinical development.
The company is also a leader in providing technology and services
to streamline the clinical trials process by enabling its customers
to automate the collection, analysis, and distribution of clinical
data in all phases of clinical development. Statements included in
this release may constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such statements involve a number of risks and uncertainties such as
competitive factors, technological development, market demand, and
the company's ability to obtain new contracts and accurately
estimate net revenues due to variability in size, scope and
duration of projects, and internal issues in the sponsoring client.
As a result, actual results may differ materially from any
financial outlooks stated herein. Further information on potential
factors that could affect the company's financial results can be
found in the company's Reports on Forms 10-K and 10-Q filed with
the Securities and Exchange Commission. DATASOURCE:
eResearchTechnology, Inc. CONTACT: Joan Sterlacci of
eResearchTechnology, +1-908-203-6473, or Matt Hayden of Hayden
Communications, +1-760-487-1137, for eResearchTechnology Web site:
http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about East Resources Acquisition Company (NASDAQ): 0 recent articles
More Eresearch Tech (MM) News Articles